PE20050131A1 - Derivados de benzoimidazol como agentes antiproliferativos - Google Patents

Derivados de benzoimidazol como agentes antiproliferativos

Info

Publication number
PE20050131A1
PE20050131A1 PE2003000864A PE2003000864A PE20050131A1 PE 20050131 A1 PE20050131 A1 PE 20050131A1 PE 2003000864 A PE2003000864 A PE 2003000864A PE 2003000864 A PE2003000864 A PE 2003000864A PE 20050131 A1 PE20050131 A1 PE 20050131A1
Authority
PE
Peru
Prior art keywords
compounds
antiproliferative agents
benzoimidazole derivatives
cr5r6
benzoimidazol
Prior art date
Application number
PE2003000864A
Other languages
English (en)
Inventor
Joseph Peter Lyssikatos
John Charles Kath
Huifen Fay Wang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20050131A1 publication Critical patent/PE20050131A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

REFERIDA A COMPUESTOS DE FORMULA I, SUS SALES, HIDRATOS Y SOLVATOS DONDE R1, R2 Y R3 SON CADA UNO H, ALQUILO C1-C6, HALO, CIANO, ENTRE OTROS; R4 ES -(CR5R6)nH, -(CR5R6)m(HETEROCICLILO DE 4 A 6 MIEMBROS); n ES 1-5; m ES 0-5. TAMBIEN REFERIDA A UN PROCESO PARA LA PREPARACION DE ESTOS COMPUESTOS CUYOS PREFERIDOS SON: 1-{2-[5-(3-MORFOLIN-4-ILPROPOXI)-BENZOIMIDAZOL-1-IL]-QUINOLIN-8-IL}PIPERIDIN-4-ILAMINA Y 1-{2-[5-(3-METIL-OXETAN-3-ILMETOXI)-BENZOIMIDAZOL-1-IL]-QUINOLIN-8-IL}PIPERIDIN-4-ILAMINA , ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS COMO EL CANCER
PE2003000864A 2002-08-28 2003-08-25 Derivados de benzoimidazol como agentes antiproliferativos PE20050131A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40652402P 2002-08-28 2002-08-28
US41704702P 2002-10-08 2002-10-08

Publications (1)

Publication Number Publication Date
PE20050131A1 true PE20050131A1 (es) 2005-03-21

Family

ID=31981411

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000864A PE20050131A1 (es) 2002-08-28 2003-08-25 Derivados de benzoimidazol como agentes antiproliferativos

Country Status (41)

Country Link
US (1) US7071337B2 (es)
EP (1) EP1594858B1 (es)
JP (1) JP4551771B2 (es)
KR (2) KR20070086768A (es)
CN (1) CN1319966C (es)
AP (1) AP2005003237A0 (es)
AR (1) AR041055A1 (es)
AT (1) ATE445610T1 (es)
AU (1) AU2003250499B2 (es)
BR (1) BRPI0313942C1 (es)
CA (1) CA2495577C (es)
CR (1) CR7698A (es)
CU (1) CU23413B7 (es)
CY (1) CY1110580T1 (es)
DE (1) DE60329715D1 (es)
DK (1) DK1594858T3 (es)
DO (1) DOP2003000694A (es)
EA (1) EA008448B1 (es)
EC (1) ECSP055633A (es)
ES (1) ES2333219T3 (es)
GE (1) GEP20064005B (es)
HK (1) HK1078571A1 (es)
HN (1) HN2003000257A (es)
HR (1) HRP20050191B1 (es)
IL (1) IL166832A (es)
IS (1) IS2738B (es)
MA (1) MA27389A1 (es)
MX (1) MXPA05001256A (es)
MY (1) MY139357A (es)
NO (1) NO20051303L (es)
NZ (1) NZ538427A (es)
OA (1) OA12916A (es)
PA (1) PA8580301A1 (es)
PE (1) PE20050131A1 (es)
PL (1) PL377678A1 (es)
PT (1) PT1594858E (es)
RS (1) RS20050180A (es)
SI (1) SI1594858T1 (es)
TW (1) TW200407131A (es)
UY (1) UY27952A1 (es)
WO (1) WO2004020431A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1641780T3 (da) * 2003-06-24 2009-02-02 Pfizer Prod Inc Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
CA2582479C (en) * 2004-10-07 2011-07-12 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
BRPI0608096A2 (pt) 2005-04-26 2009-11-10 Pfizer anticorpos p-caderina
UA94060C2 (ru) 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
BRPI0809998B8 (pt) 2007-04-03 2021-05-25 Array Biopharma Inc composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
MX2010012718A (es) * 2008-05-21 2011-04-04 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4] triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
CA2809892C (en) 2010-09-02 2019-05-28 Merck Patent Gmbh Pyrazolopyridinone derivatives as lpa receptor antagonists
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型c-kit的方法
US11642340B2 (en) 2012-09-26 2023-05-09 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
RS58328B1 (sr) * 2014-10-31 2019-03-29 Genoscience Pharma Sas Supstituisani 2,4 diamino-hinolini kao novi antitumorski agensi
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
DK3452465T3 (da) 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
WO2018085292A1 (en) 2016-11-02 2018-05-11 Arog Pharmaceuticals, Inc. Crenolanib for treating flt3 mutated proliferative disorders associated mutations
CN107382984B (zh) * 2017-08-24 2020-07-10 扬州市三药制药有限公司 一种治疗白血病药物的制备方法
CN107382983B (zh) * 2017-08-24 2020-08-07 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
CN110840893A (zh) 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN117447376A (zh) * 2019-12-09 2024-01-26 苏州恩华生物医药科技有限公司 连双环结构sigma-1受体抑制剂
WO2022019998A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
IL300205A (en) * 2020-08-05 2023-03-01 Massachusetts Gen Hospital Salt-inducible kinase inhibitors
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN113683594B (zh) * 2021-09-07 2022-12-27 曲靖师范学院 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用
JP2023063189A (ja) 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性/不応性のflt3突然変異増殖性障害を治療するためのクレノラニブ
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CA2393026A1 (en) * 1999-11-30 2001-06-07 Paul A. Wender Bryostatin analogues, synthetic methods and uses
JP2008002005A (ja) * 2006-06-21 2008-01-10 Shimada Shoji Kk 衣服用パッド

Also Published As

Publication number Publication date
UY27952A1 (es) 2004-03-31
CA2495577A1 (en) 2004-03-11
HK1078571A1 (en) 2006-03-17
EA008448B1 (ru) 2007-06-29
MA27389A1 (fr) 2005-06-01
MXPA05001256A (es) 2005-06-08
CN1678604A (zh) 2005-10-05
WO2004020431A3 (en) 2004-05-13
EP1594858A2 (en) 2005-11-16
BRPI0313942B8 (pt) 2020-08-04
US7071337B2 (en) 2006-07-04
PA8580301A1 (es) 2005-05-24
BR0313942A (pt) 2005-07-12
CA2495577C (en) 2010-06-15
NZ538427A (en) 2007-04-27
TW200407131A (en) 2004-05-16
EP1594858B1 (en) 2009-10-14
NO20051303L (no) 2005-05-18
IL166832A (en) 2011-03-31
AU2003250499A1 (en) 2004-03-19
AP2005003237A0 (en) 2005-03-31
ECSP055633A (es) 2005-04-18
SI1594858T1 (sl) 2010-01-29
BRPI0313942B1 (pt) 2019-06-04
IS2738B (is) 2011-06-15
DE60329715D1 (de) 2009-11-26
AR041055A1 (es) 2005-04-27
JP4551771B2 (ja) 2010-09-29
KR100816166B1 (ko) 2008-03-21
CR7698A (es) 2007-11-23
DOP2003000694A (es) 2004-02-29
KR20050036984A (ko) 2005-04-20
PL377678A1 (pl) 2006-02-06
KR20070086768A (ko) 2007-08-27
AU2003250499B2 (en) 2009-04-23
ES2333219T3 (es) 2010-02-18
CY1110580T1 (el) 2015-04-29
JP2006501309A (ja) 2006-01-12
HN2003000257A (es) 2004-12-01
MY139357A (en) 2009-09-30
CU23413B7 (es) 2009-09-08
OA12916A (en) 2006-10-13
DK1594858T3 (da) 2009-12-14
IS7660A (is) 2005-01-20
HRP20050191A2 (en) 2005-10-31
ATE445610T1 (de) 2009-10-15
BRPI0313942C1 (pt) 2021-05-25
US20050124599A1 (en) 2005-06-09
WO2004020431A2 (en) 2004-03-11
EA200500174A1 (ru) 2005-08-25
RS20050180A (en) 2007-08-03
CN1319966C (zh) 2007-06-06
GEP20064005B (en) 2006-12-25
HRP20050191A9 (hr) 2013-11-22
HRP20050191B1 (hr) 2013-12-20
PT1594858E (pt) 2009-12-14

Similar Documents

Publication Publication Date Title
PE20050131A1 (es) Derivados de benzoimidazol como agentes antiproliferativos
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20060297A1 (es) Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1
AR051839A1 (es) Metodo para preparar n-fenilpirazol -1- carboxamidas
FI943247A (fi) Piperatsiinijohdannaisia 5-HT-reseptoriantagonisteina
PE20030601A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
UY27357A1 (es) Nuevos agentes antidiabéticos .
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
PE20070007A1 (es) Metodos para sintetizar derivados de 6-alquilaminoquinolina
PE20040762A1 (es) Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20081174A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
PE20040528A1 (es) Inhibidores de la peptido-deformilasa
UY25143A1 (es) Procedimiento para la preparacion de inhibidores de proteasas.
PE20030208A1 (es) Derivados de indirubina que contienen azufre, su preparacion y uso
PE20050483A1 (es) Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
NZ528997A (en) Sulfonamides
PE20020253A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano como ligandos de receptores opiaceos
PE20021061A1 (es) Arilsulfonamidas como agentes antivirales
PE69398A1 (es) Antagonistas de receptor de benzoxazinona dopamina d4
PE20060529A1 (es) Metodo para preparar compuestos de pirrolotriazina
PE20040605A1 (es) Nuevas diamidas del acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de colagenesas
PE20001241A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores

Legal Events

Date Code Title Description
FG Grant, registration